- Home
- NVCR vs IRON Comparison
NVCR vs IRON Comparison
Compare NVCR & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- IRON
- Stock Information
- Founded
- NVCR 2000
- IRON 2017
- Country
- NVCR Switzerland
- IRON United States
- Employees
- NVCR N/A
- IRON N/A
- Industry
- NVCR Medical/Dental Instruments
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- IRON Health Care
- Exchange
- NVCR Nasdaq
- IRON Nasdaq
- Market Cap
- NVCR 1.9B
- IRON 1.9B
- IPO Year
- NVCR 2015
- IRON N/A
- Fundamental
- Price
- NVCR $15.58
- IRON $42.17
- Analyst Decision
- NVCR Buy
- IRON Strong Buy
- Analyst Count
- NVCR 6
- IRON 10
- Target Price
- NVCR $34.17
- IRON $83.80
- AVG Volume (30 Days)
- NVCR 736.7K
- IRON 608.5K
- Earning Date
- NVCR 04-24-2025
- IRON 05-08-2025
- Dividend Yield
- NVCR N/A
- IRON N/A
- EPS Growth
- NVCR N/A
- IRON N/A
- EPS
- NVCR N/A
- IRON N/A
- Revenue
- NVCR $605,220,000.00
- IRON N/A
- Revenue This Year
- NVCR $3.14
- IRON N/A
- Revenue Next Year
- NVCR $10.63
- IRON N/A
- P/E Ratio
- NVCR N/A
- IRON N/A
- Revenue Growth
- NVCR 18.82
- IRON N/A
- 52 Week Low
- NVCR $11.70
- IRON $25.64
- 52 Week High
- NVCR $34.13
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- NVCR 34.24
- IRON 42.98
- Support Level
- NVCR $15.49
- IRON $39.20
- Resistance Level
- NVCR $17.06
- IRON $41.41
- Average True Range (ATR)
- NVCR 1.06
- IRON 4.37
- MACD
- NVCR -0.01
- IRON 0.09
- Stochastic Oscillator
- NVCR 20.42
- IRON 54.14
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.